Kevin K. Dobbin

6.4k total citations · 1 hit paper
55 papers, 3.1k citations indexed

About

Kevin K. Dobbin is a scholar working on Molecular Biology, Statistics and Probability and Oncology. According to data from OpenAlex, Kevin K. Dobbin has authored 55 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 12 papers in Statistics and Probability and 10 papers in Oncology. Recurrent topics in Kevin K. Dobbin's work include Gene expression and cancer classification (16 papers), Molecular Biology Techniques and Applications (11 papers) and Statistical Methods in Clinical Trials (9 papers). Kevin K. Dobbin is often cited by papers focused on Gene expression and cancer classification (16 papers), Molecular Biology Techniques and Applications (11 papers) and Statistical Methods in Clinical Trials (9 papers). Kevin K. Dobbin collaborates with scholars based in United States, Uganda and Sweden. Kevin K. Dobbin's co-authors include Richard Simon, Michael D. Radmacher, Lisa M. McShane, Richard Simon, Richard H. Simon, Joanna H. Shih, Yingdong Zhao, Cheryl L. Willman, W. Paul Bowman and William L. Carroll and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Kevin K. Dobbin

53 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pitfalls in the Use of DNA Microarray Data for Diagnostic and Prognostic Classification

2003 747 citations Kevin K. Dobbin et al. profile →

Peers

Countries citing papers authored by Kevin K. Dobbin

Since Specialization

Citations

This map shows the geographic impact of Kevin K. Dobbin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin K. Dobbin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin K. Dobbin more than expected).

Fields of papers citing papers by Kevin K. Dobbin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin K. Dobbin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin K. Dobbin. The network helps show where Kevin K. Dobbin may publish in the future.

Co-authorship network of co-authors of Kevin K. Dobbin

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin K. Dobbin. A scholar is included among the top collaborators of Kevin K. Dobbin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin K. Dobbin. Kevin K. Dobbin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Performance of a score to characterise adequate contact among the social network of persons with TB 2024 ·SHILAP Revista de lepidopterología ·María Eugenia Castellanos, Sarah Zalwango, (unknown), (unknown), Leonardo Martínez, Mark H. Ebell, Kevin K. Dobbin, Noah Kiwanuka, Christopher C. Whalen	0
2	Effectiveness of a Mobile Health Intervention (DOT Selfie) in Increasing Treatment Adherence Monitoring and Support for Patients With Tuberculosis in Uganda: Randomized Controlled Trial 2024 ·JMIR mhealth and uhealth ·Juliet N. Sekandi, Esther Buregyeya, (unknown), (unknown), (unknown), (unknown), (unknown), Lynn Atuyambe, Kevin K. Dobbin	2
3	Human basal-like breast cancer is represented by one of the two mammary tumor subtypes in dogs 2023 ·Breast Cancer Research ·(unknown), Tianfang Wang, (unknown), Feng Yuan, (unknown), Kevin K. Dobbin, Shaying Zhao	5
4	Characterization of the Proportion of Clustered Tuberculosis Cases in Guatemala: Insights from a Molecular Epidemiology Study, 2010–2014 2022 ·American Journal of Tropical Medicine and Hygiene ·María Eugenia Castellanos, (unknown), (unknown), Eduardo Arathoon, Blanca Samayoa, Frederick D. Quinn, Mark H. Ebell, Kevin K. Dobbin, Christopher C. Whalen	1
5	Using a Mobile Health Intervention (DOT Selfie) With Transfer of Social Bundle Incentives to Increase Treatment Adherence in Tuberculosis Patients in Uganda: Protocol for a Randomized Controlled Trial 2020 ·JMIR Research Protocols ·Juliet N. Sekandi, (unknown), Esther Buregyeya, (unknown), (unknown), (unknown), (unknown), Lynn Atuyambe, (unknown), Kevin K. Dobbin	4
6	Defining adequate contact for transmission of Mycobacterium tuberculosis in an African urban environment 2020 ·BMC Public Health ·María Eugenia Castellanos, Sarah Zalwango, (unknown), Mark H. Ebell, Kevin K. Dobbin, Juliet N. Sekandi, Noah Kiwanuka, Christopher C. Whalen	1
7	The need for a network to establish and validate predictive biomarkers in cancer immunotherapy 2017 ·Journal of Translational Medicine ·Giuseppe Masucci, Alessandra Cesano, Alexander M.M. Eggermont, Bernard A. Fox, Ena Wang, Francesco M. Marincola, Gennaro Ciliberto, Kevin K. Dobbin, Igor Puzanov, Janis M. Taube, Jennifer A. Wargo, Lisa H. Butterfield, Lisa Villabona, (unknown), Michael A. Postow, Paul M. Sondel, Sandra Demaria, Sanjiv S. Agarwala, Paolo A. Ascierto	25
8	Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations 2016 ·Journal for ImmunoTherapy of Cancer ·Kevin K. Dobbin, Alessandra Cesano, John Alvarez, Rachael E. Hawtin, Sylvia Janetzki, Ilan R. Kirsch, Giuseppe Masucci, Paul B. Robbins, Senthamil R. Selvan, Howard Streicher, Jenny Zhang, Lisa H. Butterfield, Magdalena Thurin	78
9	Differential Toxicities of Nickel Salts to the Nematode Caenorhabditis elegans 2016 ·Bulletin of Environmental Contamination and Toxicology ·(unknown), (unknown), (unknown), Kevin K. Dobbin, Phillip L. Williams	5
10	Immune monitoring technology primer: clinical validation for predictive markers 2015 ·Journal for ImmunoTherapy of Cancer ·Kevin K. Dobbin	3
11	Canine Spontaneous Head and Neck Squamous Cell Carcinomas Represent Their Human Counterparts at the Molecular Level 2015 ·PLoS Genetics ·Deli Liu, Huan Xiong, Angela E. Ellis, Nicole C. Northrup, Kevin K. Dobbin, Dong M. Shin, Shaying Zhao	41
12	Cost-Effectiveness Analysis of Community Active Case Finding and Household Contact Investigation for Tuberculosis Case Detection in Urban Africa 2015 ·PLoS ONE ·Juliet N. Sekandi, Kevin K. Dobbin, James Oloya, Alphonse Okwera, Christopher C. Whalen, Phaedra S. Corso	55
13	Sample size requirements for training high-dimensional risk predictors 2013 ·Biostatistics ·Kevin K. Dobbin, Xiao Song	7
14	Masitinib demonstrates anti‐proliferative and pro‐apoptotic activity in primary and metastatic feline injection‐site sarcoma cells^* 2011 ·Veterinary and Comparative Oncology ·Jessica Lawrence, Corey Saba, Robert M. Gogal, (unknown), Michel L. Vandenplas, David J. Hurley, Patrice Dubreuil, Olivier Hermine, Kevin K. Dobbin, Michelle Turek	30
15	Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia 2010 ·Blood ·Richard C. Harvey, Charles G. Mullighan, I‐Ming Chen, Walker Wharton, Fady M. Mikhail, Andrew J. Carroll, Huining Kang, Wei Liu, Kevin K. Dobbin, Malcolm A. Smith, William L. Carroll, Meenakshi Devidas, W. Paul Bowman, Bruce M. Camitta, Gregory H. Reaman, Stephen P. Hunger, James R. Downing, Cheryl L. Willman	395
16	How Large a Training Set is Needed to Develop a Classifier for Microarray Data? 2008 ·Clinical Cancer Research ·Kevin K. Dobbin, Yingdong Zhao, Richard Simon	91
17	A method for constructing a confidence bound for the actual error rate of a prediction rule in high dimensions 2008 ·Biostatistics ·Kevin K. Dobbin	4
18	Practical aspects of planning, building, and interpreting tissue microarrays: The Cooperative Prostate Cancer Tissue Resource experience 2007 ·Journal of Molecular Histology ·Andre Kajdacsy‐Balla, (unknown), Virgilia Macias, Suman Setty, Nahid Nanaji, Jules J. Berman, Kevin K. Dobbin, Jonathan Melamed, Xiangzhan Kong, Maarten C. Bosland, Jan M. Orenstein, (unknown), Michael J. Becich, Rajiv Dhir, Milton W. Datta, (unknown)	36
19	Characterizing dye bias in microarray experiments 2005 ·Computer applications in the biosciences ·Kevin K. Dobbin, Ernest S. Kawasaki, David Petersen, Richard Simon	51
20	Sample size determination in microarray experiments for class comparison and prognostic classification 2004 ·Biostatistics ·Kevin K. Dobbin, Richard Simon	104

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact